Background-In individuals without known cardiovascular disease, elevated body mass index (BMI) (weight/height 2 ) is associated with an increased risk of death. However, in patients with certain specific chronic diseases, including heart failure, low BMI has been associated with increased mortality. Methods and Results-We examined the influence of BMI on prognosis using Cox proportional hazards models in 7599 patients (mean age, 65 years; 35% women) with symptomatic heart failure (New York Heart Association class II to IV) and a broad spectrum of left ventricular ejection fractions (mean, 39%) in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. During a median follow-up of 37.7 months, 1831 patients died. After adjustment for potential confounders, compared with patients with BMI between 30 and 34.9, patients in lower BMI categories had a graded increase in the risk of death. The hazard ratios (95% confidence intervals) were 1.22 (1.06 to 1.41), 1.46 (1.24 to 1.71), and 1.69 (1.43 to 2.01) among those with BMI of 25 to 29.9, 22.5 to 24.9, and Ͻ22.5, respectively. The increase in risk of death among patients with BMI Ն35 was not statistically significant (hazard ratio, 1.17; 95% confidence interval, 0.95 to 1.43). The association between BMI and mortality was not altered by age, smoking status, or left ventricular ejection fraction (P for interaction Ͼ0.20). However, lower BMI was associated with a greater risk of all-cause death in patients without edema but not in patients with edema (P for interaction Ͻ0.0001).
preserved left ventricular systolic function from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. We hypothesized that in patients with chronic HF, low BMI (and elevated BMI) would be associated with an increased risk of death and unfavorable cardiovascular outcomes.
Methods
The design and results of the CHARM program have been published previously. 16, 17 Briefly, CHARM was a multinational, double-blind, placebo-controlled program of clinical trials conducted between March 1999 and March 2003 that evaluated the efficacy of candesartan in 7599 men and women aged Ն18 years who had symptomatic chronic HF (New York Heart Association class II to IV, regardless of left ventricular ejection fraction) and were either receiving or not receiving an angiotensin-converting enzyme inhibitor at baseline. Patients with serum creatinine Ն265 mmol/L; serum potassium Ն5.5 mmol/L; known bilateral renal artery stenosis; symptomatic hypotension; critical aortic or mitral stenosis; recent myocardial infarction, stroke, or open-heart surgery (within 4 weeks); use of an angiotensin-receptor blocker in the previous 2 weeks; any noncardiac disease judged likely to limit 2-year survival; and those unwilling to provide consent, as well as women of childbearing potential not using adequate contraception, were excluded. Planned duration of treatment and follow-up ranged from 24 to 48 months.
Covariates and Outcomes
All information on covariates including demographics, height and weight, cardiovascular risk factors, symptoms and signs of HF, and concomitant medications was ascertained at the time of enrollment. Presence or absence of pitting edema in the feet, ankle, leg, or sacrum was documented. BMI was calculated as weight in kilograms divided by the square of the height in meters. The individual outcomes considered in the present investigation were all-cause death (the primary outcome of the CHARM overall program), cardiovascular death, noncardiovascular death, hospitalization for worsening HF, and hospitalization for all causes. The composite outcomes evaluated were cardiovascular death or hospitalization for worsening HF (the primary composite outcome of each of the 3 individual CHARM trials), all-cause death or hospitalization for worsening HF, and all-cause death or hospitalization for all causes. The integrated end point assessed was days alive out of hospital during 1 and 2 years of follow-up. All outcomes were determined by an independent adjudication committee using prespecified definitions and blinded to the baseline BMI status. A death was considered cardiovascular unless a specific noncardiovascular cause was identified. Hospitalization for worsening HF was defined as an unexpected admission to hospital for treatment of HF or when HF became a major component of the patient's hospital admission. A patient admitted for this reason had to show symptoms and signs of worsening HF and require treatment with intravenous diuretics. Evidence of worsening HF had to include at least 1 of the following items: increasing dyspnea on exertion, orthopnea, nocturnal dyspnea, pulmonary edema, increasing peripheral edema, increasing fatigue or decreasing exercise tolerance, renal hypoperfusion (ie, worsening renal function), raised jugular venous pressure, and radiological signs of HF.
Statistical Analyses
We evaluated BMI both as a continuous (for every 1-kg/m 2 decrease) and as a categorical variable (Ͻ22.5, 22.5 to 24.9, 25.0 to 29.9, 30.0 to 34.9 [referent], and Ն35.0 kg/m 2 ). The BMI categories were primarily based on cut points recommended by the World Health Organization 18 and endorsed by the National Institutes of Health. 19 We calculated meanϮSD for continuous variables and proportions for categorical variables at baseline for each category of BMI. We constructed linear or logistic regression models for baseline variables with BMI as a continuous variable (per 1-kg/m 2 change) and
presented probability values as an estimate of their association. To evaluate the association between BMI and the risk of various outcomes defined as time to first event, we calculated unadjusted, age-and sex-adjusted, and multivariable-adjusted hazard ratios (HRs), 95% confidence intervals (CIs), and 2-sided probability values using Cox proportional hazards regression models. We performed linear regression analyses to assess the relation between BMI and the integrated end point of days alive out of hospital during 1 year and 2 years of follow-up. In multivariable models, we adjusted for all important predictors of mortality and morbidity identified in a previous investigation in the CHARM program. 20 These variables, in the order of strength of association with all-cause death, were age (per 10 years over age 60 years), left ventricular ejection fraction (per 5% decrease below 45%), diabetes mellitus (none [referent], insulin treated, and oral therapy or diet only), male sex, New York Heart Association class (II [referent], III, and IV), current smoking, bundle-branch block, cardiomegaly, previous hospitalization for HF (none [referent] , Յ6 months, Ͼ6 months), diastolic blood pressure (per 10-mm Hg decrease), duration of HF Ͼ2 years, previous myocardial infarction, edema, heart rate (per 10-bpm increase), pulmonary crackles, pulmonary edema, mitral regurgitation, atrial fibrillation, rest dyspnea, and study treatment (candesartan versus placebo). To assess the shape of the association between BMI and all-cause death, we introduced terms with common transformations of BMI inclusive of linear, quadratic, linear plus quadratic, logarithmic, squared root, exponential, and categorical (groups as specified above) in multivariable models.
In multivariable models evaluating BMI as a continuous variable (per 1-kg/m 2 change), we examined for interaction of the effect of BMI on all-cause mortality and hospitalization for worsening HF by age (per 1-year change and as a dichotomous variable: Ͻmedian and Նmedian), smoking status (never/past smokers and current smokers), edema status (without edema and with edema), and left ventricular ejection fraction (per 5% decrease below 45% and as a dichotomous variable: Յ40% and Ͼ40%).
We performed all analyses using SAS software version 9.1. 21 We considered a 2-sided probability value of Ͻ0.05 as statistically significant.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results

Baseline Characteristics
The mean (ϮSD) and median BMIs in the CHARM cohort were 28.3 (Ϯ5.4) and 27.6, respectively, and ranged from 14.3 to 57.4 kg/m 2 . Approximately 40% of the patients with HF had BMI between 25.0 and 30.0 kg/m 2 , and Ϸ11% were in the lowest (Ͻ22.5 kg/m 2 ) and highest (Ն35 kg/m 2 ) BMI categories, respectively. BMI was inversely related to age; patients in the heaviest category were on average 8.6 years younger than patients in the leanest category (Table 1 ). Women were more likely to be in the leanest or the heaviest BMI category. Increasing BMI was associated with a higher New York Heart Association functional class, heart rate, blood pressure, and left ventricular ejection fraction. Greater proportions of individuals in lower BMI categories were current cigarette smokers and had previous history of myocardial infarction and bundle-branch block. Although the duration of HF did not differ across categories of BMI, a greater proportion of patients with lower BMI were hospitalized for HF within 6 months before enrollment. As anticipated, hypertension and diabetes mellitus were noted more commonly in higher BMI categories. Whereas ischemic heart disease was the predominant cause of HF in lower BMI categories, hypertension was the primary factor attributable to HF in higher BMI categories. Rest dyspnea, orthopnea, paroxysmal nocturnal dyspnea, and edema were more likely to be noted in individuals with higher BMI, and S 3 gallop, pulmonary crackles, pulmonary edema, and cardiomegaly were more prevalent in patients with a lower BMI. A similar proportion of individuals were on candesartan therapy in each category of BMI.
BMI and Risk of Death
During a median follow-up of 37.7 months, 1831 patients (24.1%) died. For BMI categories Ͻ35.0 kg/m 2 , crude cumulative incidence of all-cause death increased progressively with decreasing categories of BMI (Figure 1 , log-rank P of test for equality Ͻ0.0001). In unadjusted analyses, every 1-kg/m 2 decrease in BMI was associated with a 5.3% increase in the risk of all-cause death ( Table 2 ). The 26.4% increase in the risk of all-cause death among patients with BMI Ն35 in age-and sex-adjusted analyses was attenuated to 16.8% and did not reach statistical significance in fully adjusted analyses.
In multivariable analyses evaluating the shape of the association between BMI and all-cause death, linear plus quadratic BMI terms had the best goodness of fit ( 2 [2] ϭ54.9, PϽ0.0001), suggestive of a nonlinear (U-or J-shaped) association between BMI and all-cause death. Logarithmic ( 2 [1] ϭ41.8, PϽ0.0001) and categorical ( 2 [4] ϭ48.5, PϽ0.0001) terms had similar goodness of fit, followed by square root ( 2 [1] ϭ37.5, PϽ0.0001), exponential ( 2 [1] ϭ30.6, PϽ0.0001), and quadratic BMI ( 2 [1]ϭ24.7, PϽ0.0001).
Patients in lower BMI groups were at a greater risk of cardiovascular death as well as noncardiovascular death ( Table 2) . A trend was evident toward increasing noncardiovascular deaths in the highest BMI category.
BMI and Risk of Hospitalization for Worsening HF
No linear association existed between BMI and the risk of hospitalization for worsening HF ( Table 2 ). In age-and sex-adjusted models, compared with the group with BMI between 30.0 and 34.9 kg/m 2 , an 18.3% (borderline statistical significance) and 26.6% increase existed in risk of hospitalization for worsening HF in the lowest and highest category, respectively ( Table 2) . This association was attenuated and no longer significant, however, in fully adjusted models.
No statistically significant association was present between BMI and the risk of composite of cardiovascular death or hospitalization for worsening HF (data not shown). The association of BMI with the risk of the composite of all-cause death or hospitalization for worsening HF was similar to that with all-cause death alone ( Table 2 ). 
BMI and Risk of Hospitalization for All Causes
BMI and Days Alive Out of Hospital
In fully adjusted models, every 1-kg/m 2 decrease in BMI was associated with 0.6 (95% CI, 0.3 to 0.9; PϽ0.0001) and 1.9 (95% CI, 1.1 to 2.6; PϽ0.0001) fewer days alive out of hospital during 1 and 2 years of follow-up, respectively. In models evaluating BMI as a categorical variable, however, evidence existed of a possible inverted J-shaped association between BMI and days alive out of hospital characterized by a statistically significant stepwise decrease below and a decrease (albeit statistically nonsignificant) above BMI of 30 to 34.9 (Figure 2 ).
Effect Modification
The association between BMI and the risk of all-cause death and hospitalization for worsening HF did not depend on age, smoking status, or left ventricular ejection fraction (all P for interaction Ͼ0.20). Lower BMI was associated with higher risk of mortality in patients with impaired as well as preserved left ventricular ejection fraction (Table 3 ). However, lower BMI was associated with a greater risk of all-cause death in patients without edema but not in patients with edema ( Table 3 ; P for interaction Ͻ0.0001). The HRs for each 1-kg/m 2 decrease in BMI were 1.05 (95% CI, 1.03 to 1.06; PϽ0.0001) in patients without edema and 1.00 (95% CI, 0.99 to 1.02; Pϭ0.71) in patients with edema. Similar results were noted for both cardiovascular and noncardiovascular death (data not shown). Edema status or left ventricular ejection fraction at baseline did not influence the association between BMI and the risk of hospitalization for worsening HF ( Table 3 ; P for interaction Ͼ0.30).
Discussion
In CHARM patients, lowest mortality was noted in patients with BMI between 30 and 34.9, a progressive increase in mortality was evident below this range, and a plateau or increase was observed above this range (U-or J-shaped association). By the same token, highest number of days alive out of hospital during 1 or 2 years of follow-up was observed in patients with BMI between 30 and 34.9, with a stepwise decrease in days alive out of hospital below and a modest decrease above this range (inverted J-shaped association Few studies have addressed the issue of shape of the association between BMI and all-cause death in chronic HF patients. In a report from the Digitalis Investigation Group (DIG) trial, unadjusted analyses using polynomial logistic regression revealed a nonlinear association between BMI and death. 13 In the present investigation, age-and sex-adjusted as well as multivariable time-to-event analyses that accounted for major indicators of poor prognosis also suggest a nonlinear (Uor J-shaped) relation between BMI and mortality. Commensurate with this finding, an inverted J-shaped association was noted between BMI and days alive out of hospital, a type of quality of life-adjusted survival that accounted for multiple hospitalizations during the period of evaluation.
Edema increases BMI on the basis of fluid excess rather than solid tissue mass. Results of our investigation suggest that in patients with chronic HF, baseline BMI can be a useful indicator of mortality primarily in the absence of edema.
In the DIG trial 13 as well as in our present investigation, in which relatively younger (mean age, 63 to 65 years) and stable HF patients were enrolled, left ventricular systolic dysfunction, as assessed by estimates of left ventricular ejection fraction, did not alter the effects of BMI on the risk of all-cause death. In the Danish Investigations of Arrhythmia and Mortality (DIAMOND) congestive heart failure study, in which older (mean age, 72 years) HF patients admitted for new-onset or worsening HF were enrolled, in patients with left ventricular systolic dysfunction, as assessed by wall motion index, higher BMI was associated with a greater risk of all-cause death, whereas in patients with normal left ventricular systolic function, lower BMI posed a greater risk of all-cause death. 12 The differences in study population and mode of ascertainment of left ventricular systolic function may partially explain the disparity in interaction of left ventricular function and BMI and the risk of mortality.
In our analyses as well as in the study by DIG investigators, 13 BMI did not influence the risk of hospitalization for HF in multivariable analyses. The lack of association with this sensitive clinical measure of HF severity, along with the similarity of effect of BMI on cardiovascular and noncardiovascular deaths, suggests that low BMI is a general marker (not a causal factor) of ill health.
A number of hypotheses have been put forth to explain the association between lower BMI and increased risk of mortality in HF patients. [22] [23] [24] [25] Lower BMI in patients with "prevalent" HF, as in the present and other previously published studies, [7] [8] [9] [11] [12] [13] [14] may have been due to preceding involuntary weight loss or cardiac cachexia, a heightened metabolic or increased catabolic state 26 associated with worse prognosis. 8, 27, 28 By the same token, higher BMI, except when produced by edema, might indicate a greater metabolic reserve, increased tolerance to metabolic stress, 29 and/or a less severe form of HF, and consequently may have a better prognosis. 30 Elevated BMI may be associated with reduced cardiac sympathetic activity, 31 attenuated neurohormonal response to stress, 32 lower proinflammatory cytokine levels, and lesser catabolic-anabolic imbalance, 33 all of which bode a better prognosis. Increased production of leptin 34 and soluble receptors of tumor necrosis factor 35 in adipose tissues may reduce the detrimental effects of tumor necrosis factor, a proinflammatory cytokine. Individuals with higher BMI, presumably due to lower natriuretic peptide levels, 36, 37 may manifest symptoms and signs of HF at a younger age with consequent longer survival after diagnosis (lead-time bias).
Elevated BMI may increase the risk of death and unfavorable cardiovascular outcomes by promoting risk factors for cardiovascular disease 19, 38 and by influencing abnormal left ventricular remodeling. 39 Extreme BMI may continue to pose greater hemodynamic stress on the heart that could be deleterious. The improvement in functional class and pump function noted in smaller studies in which extremely obese HF patients have undergone marked weight reductions 40, 41 lends credence to this notion.
The strengths of our investigation include a large sample size, multicenter setting, inclusion of a broad spectrum of left ventricular ejection fractions in patients with symptomatic HF on evidence-based treatments in a contemporary time period, assessment of edema status, availability of information on most covariates of interest (including duration of HF) for multivariable analyses, nearly complete follow-up of patients during the 2-to 4-year study period, and objective ascertainment of all study end points by an independent committee blinded to BMI status at enrollment. Several limitations of these analyses should also be noted. We did not have data on body weights at the time of first diagnosis of HF to ascertain the influence of weight change subsequent to the time of first diagnosis on the risk of death or cardiovascular outcomes. Selection bias is likely in all prognostic studies conducted on patients with prevalent HF (in which BMI at the time of onset of HF is unavailable, and changes in body weight preceding their inclusion in various categories of BMI are uncertain). 24 and fat tissue) on the risk of clinical outcomes. 42 Results of analyses stratified according to baseline edema status should be interpreted with caution given the small sample size of patients with edema in lower-BMI groups. We did not have other baseline data such as serum albumin levels for all participants, which may have allowed further elucidation of underweight status versus cardiac cachexia (or protein-calorie malnutrition) in patients with the lowest BMI values. Higher-BMI patients with HF were younger at the time of enrollment than lower-BMI patients, suggesting lead-time bias as a possible explanation for the association between higher BMI and better survival. However, the similar duration of HF in all BMI groups and absence of interaction between age and BMI and the risk of death in multivariable analyses do not support this explanation. Because a majority of patients studied were of European origin, the generalizability of our findings to other races and ethnic groups is another limitation.
We conclude that in patients with symptomatic and chronic HF, underweight status or low BMI is associated with a No. of events/at risk (%), rate/100 py greater risk of all-cause death, and mild to moderate overweight status is associated with the lowest risk. The implication of moderate to extreme BMI on prognosis is uncertain. Lower BMI is an indicator of poor survival, primarily in the absence of fluid overload. Our findings warrant additional research, especially in community-based settings among patients with new-onset HF, to assess the impact of BMI, ascertained in close proximity to the first diagnosis of HF, on morbidity and mortality.
